ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.
Emcure Pharmaceuticals has filed its Annual Report for the financial year 2025-26 and the notice for its 45th Annual General Meeting.
Emcure Pharmaceuticals has allotted 19,100 equity shares to employees following the exercise of vested ESOPs. The paid-up capital of the company has increased accordingly.
Emcure Pharmaceuticals received an Establishment Inspection Report (EIR) from the USFDA, classifying its Sanand facility inspection as 'Voluntary Action Indicated' and effectively closing the inspection.
Emcure's Q1 FY27 results show strong performance driven by international markets and HIV (ARV) business, despite a transitional period in domestic operations following organizational restructuring and the acquisition of Sanofi and Roche portfolios.
Emcure Pharmaceuticals will hold its 45th AGM on September 21, 2026. The company fixed September 04, 2026, as the record date for a Rs. 3.60 per share dividend.
Emcure Pharmaceuticals announced a board reorganization. Mr. Raghu Kumar was appointed as Additional Independent Director, while Mr. Satish Mehta will become Chairman following Mr. Berjis Desai's retirement.
Emcure reported Q1 FY27 revenue growth of 22.8% YoY with PAT margins expanding 110 bps. Growth was driven by a 34.2% surge in International Business (58% of total revenue).
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,580 Cr (+22.8% YoY) and net profit of ₹292.5 Cr (+36.2% YoY) for Q1 FY27.
Emcure completed the acquisition of a 12.05% stake in Gennova Biopharmaceuticals for ₹231.87 Crore, making it a wholly-owned subsidiary.
Mr. P.S. Jayakumar has ceased to be an Independent Director of Emcure Pharmaceuticals Limited effective July 21, 2026, following the completion of his second consecutive term.
Emcure Pharmaceuticals filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing includes details of promoter and public shareholdings.
Emcure received CDSCO approval to expand the use of its drug Poviztra for treating MASH. This milestone allows the company to address a significant unmet medical need.
Emcure Pharmaceuticals will hold a board meeting on August 06, 2026. The board will consider unaudited standalone and consolidated financial results for Q1 FY27.
Emcure Pharmaceuticals acquires 12.05% minority stake in Gennova Biopharmaceuticals, making it a wholly-owned subsidiary. The move consolidates ownership to sharpen focus on biologics.
Emcure Pharmaceuticals will acquire a 12.05% stake in Gennova Biopharmaceuticals for Rs. 231.87 Crore. This transaction will make Gennova a wholly-owned subsidiary by July 2026.
Emcure's subsidiary, Gennova Biopharmaceuticals, will sell its mRNA business to Immunoscript Life Science for Rs. 139.5 Crore. The slump sale aligns with strategic business reorganization.